The investigation whether Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. violated the Act no. 4054 by means of abusing its dominant position via refusal to supply goods to Çınar Ecza Deposu ve Dış Tic. A.Ş. and by preventing competition at pharmaceuticals wholesale level by obliging pharmaceutical warehouses it worked with not to make sales to other pharmaceutical warehouses was concluded.

As a result of the discussion of the contents of the file on 11.04.2019, the Competition Board decided that Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. and Alcon Laboratuvarları Tic. A.Ş. did not violate the Act no 4054; thus, it was not necessary to impose administrative fines on the said undertakings according to article 16 of the same Act.

Click here for the text of the pronouncement of the decision dated 11.04.2019 and numbered 19-15/215-95, the reasoned decision for which will be notified later and which can be appealed before Ankara Administrative Courts.